Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease

Bone ◽  
2014 ◽  
Vol 64 ◽  
pp. 33-38 ◽  
Author(s):  
Daniel Cejka ◽  
Michael Weber ◽  
Danielle Diarra ◽  
Thomas Reiter ◽  
Franz Kainberger ◽  
...  
2000 ◽  
Vol 342 (20) ◽  
pp. 1478-1483 ◽  
Author(s):  
William G. Goodman ◽  
Jonathan Goldin ◽  
Beatriz D. Kuizon ◽  
Chun Yoon ◽  
Barbara Gales ◽  
...  

2015 ◽  
Vol 88 (6) ◽  
pp. 1356-1364 ◽  
Author(s):  
Abdul Rashid Qureshi ◽  
Hannes Olauson ◽  
Anna Witasp ◽  
Mathias Haarhaus ◽  
Vincent Brandenburg ◽  
...  

Renal Failure ◽  
2011 ◽  
Vol 33 (8) ◽  
pp. 770-775 ◽  
Author(s):  
Halil Zeki Tonbul ◽  
Kultigin Turkmen ◽  
Hatice Kayıkcıoglu ◽  
Orhan Ozbek ◽  
Mehmet Kayrak ◽  
...  

1998 ◽  
Vol 9 (10) ◽  
pp. 1940-1947 ◽  
Author(s):  
W M McClellan ◽  
J M Soucie ◽  
W D Flanders

Death rates of end-stage renal disease (ESRD) patients treated with hemodialysis vary substantially among treatment centers. The association between facility-to-facility differences in delivered hemodialysis dose and facility-specific mortality rates was examined among 5817 randomly selected patients treated with hemodialysis on October 1, 1994, from all 213 hemodialysis treatment centers reporting to ESRD Network 6. The mean urea reduction ratio (URR) for each treatment center, a measure of hemodialysis adequacy, was calculated for each facility, using measurements made by center staff members during one treatment for each of the randomly selected patients. During 7 mo of follow-up (ending April 30, 1995), 441 (7.6%) patients died. The average URR among the treatment centers was 64.9%. There was a strong, inverse association between increasing treatment center URR and adjusted mortality count (P = 0.009). Other treatment center characteristics associated with increased mortality included free-standing status (P = 0.009) and decreasing frequency of reported physician supervision of care (P = 0.01). It was concluded that lower average levels of dialysis adequacy in treatment centers are associated with higher rates of death, and this association persists after controlling for facility-to-facility differences in patient and nonpatient characteristics.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Mark D Benson ◽  
Cathryn Byrne-Dugan ◽  
Dale Adler ◽  
Mark Feinberg ◽  
Deepak Bhatt

A 54-year-old man with remote large cell non-Hodgkin’s lymphoma in remission following R-CHOP and severe atopic dermatitis was transferred from another hospital with a non-ST elevation myocardial infarction. Over the preceding year, the patient had suffered recurrent admissions for acutely decompensated heart failure with a newly depressed left ventricular ejection fraction (LVEF) of 20% by echocardiography and rapidly progressive end-stage renal disease of unclear etiology requiring the initiation of hemodialysis. Prior workup had demonstrated an infrarenal abdominal aortic aneurysm and bilateral common iliac artery aneurysms with subsequent computed tomography (CT) additionally demonstrating a superior mesenteric artery aneurysm. The patient was taken for immediate coronary arteriography, which demonstrated giant aneurysms in the left main and right coronary arteries, as well as multivessel severe stenoses. CT coronary angiogram demonstrated significant circumferential wall thickening throughout the coronary vasculature. Given concern for IgG4-related disease (IgG4-RD), a renal biopsy was pursued that confirmed the diagnosis. 18F-fluorodeoxyglucose positron emission tomography-CT identified only mild aortic inflammation. The patient was treated with high-dose steroids and rituximab. The serological inflammatory markers improved, and he underwent coronary artery bypass grafting. Pericardial, aortic adventitial, left internal mammary artery, and saphenous vein biopsies showed cardiovascular involvement of IgG4-RD. The patient has been maintained on rituximab with normalization of his LVEF and no recurrence of chest pain over the past eighteen months. IgG4-RD is a fibroinflammatory systemic disease newly described in 2003 and only recently found to involve the cardiovascular system with several reports of peripheral aneurysmal disease. To our knowledge, the current case represents the first report of a patient successfully treated for biopsy-proven IgG4-RD associated with coronary artery disease and left ventricular systolic dysfunction. IgG4-RD may represent a novel mechanism underlying some forms of peripheral and coronary arterial disease and may offer new insights into vascular biology.


Sign in / Sign up

Export Citation Format

Share Document